Posted by Michael Wonder on 10 Jun 2024
FDA approves Almirall’s Klisyri (tirbanibulin) for the treatment of actinic keratosis on expanded area of face or scalp up to 100 cm2
10 June 2024 - Original FDA approval (December 2020) now extended to the use of Klisyri on larger areas of the face or scalp (up to 100 cm2) to address more extensive manifestations of actinic keratosis, driving convenience for both patients and dermatologists.
Almirall announced today that the US FDA has approved Almirall’s recent supplemental new drug application to expand the use area for its drug, Klisyri, to up to 100 cm2.
